Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. GlycoGenesys was originally founded in 1992 as IGG International Inc to pursue carbohydrate-based pharmaceutical research for cancer therapeutics. In 1995, the company merged with Alvarada Inc, a publicly-traded corporation having no active operations. In 1998, the company changed its name to SafeScience Inc and in October 2001, its name was changed to GlycoGenesys Inc to emphasise its focus on the development of carbohydrate-based cancer therapeutics.